ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
Portola Pharmaceuticals Inc.
18.03
0.0000
成交量:
- -
成交额:
- -
市值:
14.16亿
市盈率:
-4.76
高:
18.03
开:
18.03
低:
18.03
收:
18.03
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
Portola Pharmaceuticals Inc.
交易所:
NASDAQ
成立时间:
- -
员工人数:
- -
公司地址:
- -
官网:
http://www.portola.com
邮编:
- -
电话:
- -
传真:
- -
简介:
Portola Pharmaceuticals, Inc.是一家生物制药企业。公司致力于在血栓疾病以及其他血液疾病和发炎病症领域研发新的疗法,同时将该疗法商业化。该疗法主要用于当前没有或认证疗法选择有限的病人。公司于2003年9月在特拉华州注册成立。公司总部以及业务范围在加利福尼亚州的南旧金山市,并以一个部门生产经营。 公司两个主要项目用于解决血栓疾病和血凝块方面的问题。公司主要化合物是新型口服每日一次的贝曲西班,它是处于第三研发阶段凝血因子Xa的抑制剂,主要用于急性内科疾病患者静脉血栓栓塞的长期预防或预防性疗法。公司第二主要的候选研发药物是正处于概念取证阶段的PRT4445,它是一个主要用于逆转抗凝血生理活动的重组蛋白,该药主要用于使用抗凝血因子抑制剂治疗的患有不可控流血疾病或经历急诊外科手术的患者。公司第三种候选产品PRT2070是一种可口服的激酶抑制剂,该药物主要用于血液系统疾病、血液疾病、癌症及其他发炎类疾病。公司第四候选产品是 PRT2607,该药物由公司合作伙伴百健艾迪股份有限公司(Biogen Idec Inc.)开发研制,主要用于发炎类疾病。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PTLA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","market":"US","secType":"STK","nameCN":"Portola Pharmaceuticals Inc.","latestPrice":18.03,"timestamp":1593633600000,"preClose":18.03,"halted":3,"volume":0,"delay":0,"floatShares":73226120,"shares":78517282,"eps":-3.784152,"marketStatus":"停牌","change":0,"latestTime":"05-29 10:33:49 EDT","open":18.03,"high":18.03,"low":18.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.784152,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1748548800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1369195200000,"exchange":"NASDAQ","adjPreClose":18.03,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","floatShares":73226120,"roa":"-30.59%","roe":"-462.25%","lyrEps":-4.062079,"shares":78517282,"dividePrice":0,"high":18.03,"amplitude":0,"preClose":18.03,"low":18.03,"week52Low":5.31,"pbRate":"19.65","week52High":31.73,"institutionHeld":0,"latestPrice":18.03,"eps":-3.784152,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.784152,"open":18.03,"prevYearClose":23.88},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.portola.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.067},{"period":"3month","weight":0.0046},{"period":"6month","weight":-0.0246},{"period":"1year","weight":0.1093},{"period":"ytd","weight":0.0028}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Portola Pharmaceuticals, Inc.是一家生物制药企业。公司致力于在血栓疾病以及其他血液疾病和发炎病症领域研发新的疗法,同时将该疗法商业化。该疗法主要用于当前没有或认证疗法选择有限的病人。公司于2003年9月在特拉华州注册成立。公司总部以及业务范围在加利福尼亚州的南旧金山市,并以一个部门生产经营。 公司两个主要项目用于解决血栓疾病和血凝块方面的问题。公司主要化合物是新型口服每日一次的贝曲西班,它是处于第三研发阶段凝血因子Xa的抑制剂,主要用于急性内科疾病患者静脉血栓栓塞的长期预防或预防性疗法。公司第二主要的候选研发药物是正处于概念取证阶段的PRT4445,它是一个主要用于逆转抗凝血生理活动的重组蛋白,该药主要用于使用抗凝血因子抑制剂治疗的患有不可控流血疾病或经历急诊外科手术的患者。公司第三种候选产品PRT2070是一种可口服的激酶抑制剂,该药物主要用于血液系统疾病、血液疾病、癌症及其他发炎类疾病。公司第四候选产品是 PRT2607,该药物由公司合作伙伴百健艾迪股份有限公司(Biogen Idec Inc.)开发研制,主要用于发炎类疾病。","exchange":"NASDAQ","name":"Portola Pharmaceuticals Inc.","nameEN":"Portola Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-11","symbol":"PTLA","fiscalQuarterEnding":"2020/03","expectedEps":-0.74,"name":null,"time":"盘后","type":"earning","dateTimestamp":1589169600000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2020-02-26","symbol":"PTLA","fiscalQuarterEnding":"2019/12","expectedEps":-0.89,"name":null,"time":"盘后","type":"earning","dateTimestamp":1582693200000,"reportTimeType":"post","actualEps":-1.24},{"date":"2019-11-05","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.82,"defaultRemindTime":1572987600000,"name":null,"time":"盘后","dateTimestamp":1572930000000,"actualEps":null},{"date":"2019-08-07","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-1.05,"defaultRemindTime":1565208000000,"name":null,"time":"盘后","dateTimestamp":1565150400000,"actualEps":-1.61},{"market":"US","date":"2019-05-08","symbol":"PTLA","fiscalQuarterEnding":"2019/03","expectedEps":-1.02,"name":null,"time":"盘前","type":"earning","dateTimestamp":1557288000000,"reportTimeType":"pre","actualEps":-1.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTLA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTLA","date":"2020-07-02","current":-5.03298,"percent":0.525692,"low":-8.397919,"twenty":-7.298314,"median":-5.390954,"eighty":-3.580615,"high":-1.552673,"avg":-5.298922,"sd":2.018062,"marketCap":1415666594},"quantilePoints":[{"date":"2020-05-29","current":-5.010649,"twenty":-7.402509,"median":-5.526738,"eighty":-2.793215,"marketCap":1409385211},{"date":"2020-06-05","current":-4.999483,"twenty":-7.3879,"median":-5.503934,"eighty":-3.318955,"marketCap":1406244520},{"date":"2020-06-12","current":-5.007857,"twenty":-7.377786,"median":-5.445889,"eighty":-3.477053,"marketCap":1408600039},{"date":"2020-06-19","current":-4.999483,"twenty":-7.3227,"median":-5.410647,"eighty":-3.515062,"marketCap":1406244520},{"date":"2020-06-26","current":-5.016231,"twenty":-7.305342,"median":-5.404428,"eighty":-3.549216,"marketCap":1410955557},{"date":"2020-07-02","current":-5.03298,"twenty":-7.298314,"median":-5.390954,"eighty":-3.580615,"marketCap":1415666594}],"updateTime":1748527491062}}}